Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ketamine for the Treatment of Depression in Parkinson's Disease (KET-PD)

NCT04944017 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT04944017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04944017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ketamine for the Treatment of Depression in Parkinson's Disease (KET-PD)
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Completed
Start date
November 23, 2021
Completion date
September 24, 2025
Enrollment
51 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression, parkinson's disease